Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
作者信息
Garfall Alfred L, Stadtmauer Edward A, Hwang Wei-Ting, Lacey Simon F, Melenhorst Jan Joseph, Krevvata Maria, Carroll Martin P, Matsui William H, Wang Qiuju, Dhodapkar Madhav V, Dhodapkar Kavita, Das Rituparna, Vogl Dan T, Weiss Brendan M, Cohen Adam D, Mangan Patricia A, Ayers Emily C, Nunez-Cruz Selene, Kulikovskaya Irina, Davis Megan M, Lamontagne Anne, Dengel Karen, Kerr Naseem Ds, Young Regina M, Siegel Donald L, Levine Bruce L, Milone Michael C, Maus Marcela V, June Carl H
出版信息
JCI Insight. 2019 Feb 21;4(4). doi: 10.1172/jci.insight.127684.
Abstract
摘要
相似文献
1
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.抗CD19嵌合抗原受体T细胞联合大剂量美法仑及自体干细胞移植治疗难治性多发性骨髓瘤
JCI Insight. 2019 Feb 21;4(4). doi: 10.1172/jci.insight.127684.
2
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.抗 CD19 CAR T 细胞联合大剂量美法仑和自体干细胞移植治疗难治性多发性骨髓瘤。
JCI Insight. 2018 Apr 19;3(8). doi: 10.1172/jci.insight.120505.
3
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
4
Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma.用于治疗多发性骨髓瘤的靶向CD19的嵌合抗原受体T细胞
N Engl J Med. 2015 Sep 10;373(11):1040-7. doi: 10.1056/NEJMoa1504542.
5
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.一项关于大剂量来那度胺和美法仑作为复发或难治性多发性骨髓瘤自体干细胞移植预处理的I期试验。
Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. doi: 10.1016/j.bbmt.2017.03.007. Epub 2017 Mar 8.
6
A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.一项关于递增剂量硼替佐米联合大剂量美法仑作为多发性骨髓瘤患者挽救性自体外周血干细胞移植预处理方案的I/II期研究。
Biol Blood Marrow Transplant. 2016 Dec;22(12):2165-2171. doi: 10.1016/j.bbmt.2016.08.017. Epub 2016 Aug 31.
7
High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial.高剂量美法仑联合自体移植治疗难治性多发性骨髓瘤：西南肿瘤协作组II期试验结果
J Clin Oncol. 1999 Jul;17(7):2173-9. doi: 10.1200/JCO.1999.17.7.2173.
8
Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib.适合自体干细胞移植的多发性骨髓瘤患者中预处理方案毒性的比较：大剂量美法仑与大剂量美法仑联合硼替佐米
J Oncol Pharm Pract. 2018 Jun;24(4):281-289. doi: 10.1177/1078155217697486. Epub 2017 Mar 21.
9
Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.半相合CD19嵌合抗原受体T细胞与干细胞共同输注在难治性急性淋巴细胞白血病中实现了完全供者植入。
J Hematol Oncol. 2016 Nov 25;9(1):131. doi: 10.1186/s13045-016-0357-z.
引用本文的文献
1
Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods.当前抗骨髓瘤嵌合抗原受体T细胞：新靶点与新方法
Balkan Med J. 2025 Jul 1;42(4):301-310. doi: 10.4274/balkanmedj.galenos.2025.2025-4-25.
2
Depletion of Tregs from CD4 CAR-T cells enhances the tumoricidal effect of CD8 CAR-T cells in anti-CD19 CAR-T therapy.在抗CD19嵌合抗原受体T细胞（CAR-T）疗法中，从CD4 CAR-T细胞中去除调节性T细胞（Tregs）可增强CD8 CAR-T细胞的杀瘤效果。
FEBS J. 2025 Apr;292(8):1904-1919. doi: 10.1111/febs.17326. Epub 2024 Dec 4.
3
miR-34a promotes the immunosuppressive function of multiple myeloma-associated macrophages by dampening the TLR-9 signaling.miR-34a 通过抑制 TLR-9 信号通路促进多发性骨髓瘤相关巨噬细胞的免疫抑制功能。
Cancer Med. 2024 Jun;13(11):e7387. doi: 10.1002/cam4.7387.
4
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.双特异性 CAR T 细胞疗法靶向复发/难治性多发性骨髓瘤的 BCMA 和 CD19：一项 I/II 期试验。
Nat Commun. 2024 Apr 20;15(1):3371. doi: 10.1038/s41467-024-47801-8.
5
Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma.自体造血干细胞移植联合嵌合抗原受体T细胞疗法治疗多发性骨髓瘤的研究进展与展望
Ther Adv Hematol. 2024 Mar 13;15:20406207241237594. doi: 10.1177/20406207241237594. eCollection 2024.
6
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts.经新型 VHH 基嵌合抗原受体修饰的 T 细胞对 CD19 表现出与 FMC63 基嵌合抗原受体相当的肿瘤杀伤效力。
Front Immunol. 2023 Feb 16;14:1063838. doi: 10.3389/fimmu.2023.1063838. eCollection 2023.
7
Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.了解多发性骨髓瘤中常用表面抗原的生物活性及预后意义
J Clin Med. 2022 Mar 25;11(7):1809. doi: 10.3390/jcm11071809.
8
Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.多发性骨髓瘤靶向免疫治疗新前沿的有前景抗原
Cancers (Basel). 2021 Dec 6;13(23):6136. doi: 10.3390/cancers13236136.
9
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.将 CAR 与嵌合共刺激受体结合可增强 T 细胞对低抗原密度的敏感性，并促进其持久性。
Sci Transl Med. 2021 Dec 8;13(623):eabh1962. doi: 10.1126/scitranslmed.abh1962.
10
Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges.嵌合抗原受体 T 细胞疗法在肺癌中的应用：潜力与挑战。
Front Immunol. 2021 Nov 1;12:782775. doi: 10.3389/fimmu.2021.782775. eCollection 2021.
Zotero 插件